According to a new market research report, the next generation sequencing industry is expected to grow from $12,982.08 million in 2023 to $97,813.73 million by 2035, registering a compound annual growth rate (CAGR) of 18.3% from 2024 to 2035. This extraordinary growth trajectory places next generation sequencing among the fastest-expanding segments in the entire global life sciences and diagnostics landscape. The technology’s ability to deliver rapid, high-resolution genomic insights at continuously declining costs is reshaping the boundaries of clinical diagnostics, drug discovery, agricultural science, and public health surveillance in ways that were scarcely imaginable just a decade ago.
Next generation sequencing, also commonly referred to as NGS, second generation sequencing, or massively parallel sequencing, is a transformative molecular technology used to determine the order of nucleotides across entire genomes or precisely targeted regions of DNA or RNA at high speed and remarkably low cost compared to earlier sequencing methodologies. This technology is being deployed with growing frequency for the identification of biomarkers that enable early disease diagnosis, as well as for the development of personalized treatment strategies that represent a fundamental departure from the traditional one-size-fits-all model of medical care. The resulting shift toward a precision medicine paradigm is one of the most consequential developments in modern healthcare, and NGS is at its technological core.
Access Sample Data & Findings:
https://www.alliedmarketresearch.com/request-sample/2048
Several powerful forces are converging to drive the growth of the global NGS market. The rising prevalence of genetic disorders and various forms of cancer is creating urgent clinical demand for the kind of comprehensive genomic profiling that only NGS can reliably deliver at scale. The increasing adoption of precision medicine frameworks by healthcare providers, payers, and regulators is further amplifying demand, as genomic data becomes central to treatment decision-making across oncology, rare disease management, reproductive health, and infectious disease monitoring.
High-end technological advancements in NGS platforms, a surge in the breadth of NGS applications across research and clinical settings, and the continued growth of genome mapping programs funded by governments and private institutions worldwide are all contributing meaningfully to market expansion.
At the same time, several challenges continue to shape the competitive and regulatory environment for NGS. Standardization concerns over NGS-based diagnostics remain a significant issue, as the lack of universally accepted protocols and quality benchmarks can complicate the clinical validation and regulatory approval of NGS assays. The shortage of professionals with the specialized bioinformatics and genomics expertise needed to operate NGS platforms and interpret their outputs effectively represents another structural barrier, particularly in markets where genomics education and training infrastructure is still developing. Ethical and legal considerations surrounding the collection, storage, and use of genetic data also introduce complexity, requiring market participants to navigate an evolving and jurisdiction-specific landscape of privacy regulations and informed consent requirements.
The COVID-19 pandemic demonstrated in compelling fashion the strategic value of NGS technology in public health emergency response. NGS diagnostic technology proved capable of determining the complete genetic sequence of the SARS-CoV-2 virus, enabling scientists to track mutations, identify new variants, and develop targeted countermeasures with unprecedented speed. Genome sequencing played a vital role in understanding the geographic spread of COVID-19 and informing the development of interventions and treatment protocols.
Initiatives such as the COVID-19 Genomics UK Consortium, formed in March 2020 to analyze the coronavirus genome through whole-genome sequencing, highlighted the immense potential of NGS as a frontline tool in pandemic surveillance and response. The pandemic has left a lasting positive imprint on the NGS market by raising awareness and accelerating investment in genomic surveillance infrastructure globally.
Examining the market by product type, the consumables segment accounted for more than two-thirds of total market revenue and is projected to maintain its dominant position throughout the forecast period. This leadership reflects the ongoing, recurring nature of consumable demand throughout the sample preparation process and other prerequisite steps of NGS workflows. The services segment, encompassing bioinformatics analysis, data interpretation, and managed genomics services, is expected to register the fastest CAGR of 19.3% during the forecast period, driven by the growing preference among research institutions and clinical laboratories for outsourced, turnkey genomics solutions that reduce the need for in-house expertise and infrastructure investment.
★ See What’s Inside This Report @
https://www.alliedmarketresearch.com/purchase-enquiry/2048
By application, the biomarker discovery and cancer genomics segment was the highest revenue contributor in the base year and is projected to grow at a CAGR of 17.5% through the forecast period, reflecting the central role of NGS in oncology research, liquid biopsy development, and companion diagnostic programs. By technology, sequencing by synthesis represented the largest revenue share, owing to its high accuracy, scalability, and broad compatibility with a wide range of clinical and research applications.
Regionally, North America occupied the dominant position, supported by high levels of R&D investment, the presence of leading NGS platform manufacturers and service providers, and a well-established healthcare infrastructure. Asia-Pacific, however, is projected to register the highest CAGR of 19.0% during the forecast period, as governments across the region increase their investment in healthcare infrastructure modernization, genomics research programs, and the expansion of precision medicine capabilities to serve their large and growing populations.
Looking toward the coming decade, the next generation sequencing market is positioned for extraordinary growth, underpinned by the convergence of declining sequencing costs, expanding clinical applications, increasing cloud computing and data management capabilities, and a global healthcare system increasingly committed to the promise of precision medicine. Organizations that invest in scalable platforms, robust bioinformatics infrastructure, and strategic partnerships across the research, clinical, and agricultural genomics ecosystems will be exceptionally well-positioned to capture a meaningful share of what is set to become one of the most valuable markets in the entire life sciences industry by 2035.
About Us
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides end-to-end solutions along with information, education, advocacy, and networking resources to SMEs and early-stage start-ups to bring excellence to their processes. In addition, we offer a nurturing environment required to develop and grow businesses, including business planning; virtual support; market intelligence; acquiring resources; and getting direct access to finance, suppliers, and other experts to boost the growth of businesses and entrepreneurs.
Our bundled and hassle-free business support systems are customized to meet the needs of SME consultants and industry leaders. Moreover, our large network of skilled consultants and experts help start-ups get the business on a roll.
Contact:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
